With the understanding and deepening of the regulatory mechanism of eIF4A1, we found that eIF4A1 can be one of the potential points of action and biomarkers for cancer diagnosis and therapy (HAN et al., 2022). The gene discussed is EIF4A1; the disease is cancer.